New preclinical work from Stanford Medicine and UCSF links tau pathology to mitochondrial reverse electron transport (RET), offering a mechanism that could be targeted beyond conventional tau aggregation narratives. Researchers reported in Neuron that chemically modified tau enters mitochondria and interferes with the electron transport chain, triggering a RET-driven cascade associated with reactive oxygen species, stress signaling, and neurodegeneration. The study suggests RET may serve as a common pathogenic bridge across multiple tauopathies, reframing how tau contributes to mitochondrial failure. The authors reported that blocking this RET-associated phenomenon reduced harmful effects and improved learning and memory in flies and mice, with supporting signals from human cell models and patient brain tissue. For therapeutic development, the mechanism points to intervention opportunities downstream of tau’s intracellular trafficking into mitochondria—an area where drugs could be designed to modulate specific metabolic steps rather than only prevent aggregation.